Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1,619.70
0.05 EUR
1.14 M EUR
158.15 M EUR
13.12 M
About PHARMA MAR, S.A.
Sector
CEO
José Maria Fernández de Sousa-Faro
Headquarters
Colmenar Viejo
Website
Founded
1986
ISIN
ES0169501022
FIGI
BBG00XH531T0
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange PHARMA MAR SA stocks are traded under the ticker PHME.
We've gathered analysts' opinions on PHARMA MAR SA future price: according to them, PHME price has a max estimate of 95.00 EUR and a min estimate of 29.60 EUR. Watch PHME chart and read a more detailed PHARMA MAR SA stock forecast: see what analysts think of PHARMA MAR SA and suggest that you do with its stocks.
PHME reached its all-time high on Oct 16, 2020 with the price of 147.80 EUR, and its all-time low was 10.85 EUR and was reached on Oct 26, 2018. View more price dynamics on PHME chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track PHARMA MAR SA financials in yearly and quarterly reports right on TradingView.
PHARMA MAR SA is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
PHME earnings for the last quarter are 0.22 EUR per share, whereas the estimation was 0.20 EUR resulting in a 7.32% surprise. The estimated earnings for the next quarter are −0.37 EUR per share. See more details about PHARMA MAR SA earnings.
PHARMA MAR SA revenue for the last quarter amounts to 45.85 M EUR, despite the estimated figure of 45.77 M EUR. In the next quarter, revenue is expected to reach 34.80 M EUR.
PHME net income for the last quarter is 3.90 M EUR, while the quarter before that showed 1.24 M EUR of net income which accounts for 215.60% change. Track more PHARMA MAR SA financial stats to get the full picture.
PHARMA MAR SA dividend yield was 1.58% in 2023, and payout ratio reached 1.02 K%. The year before the numbers were 0.82% and 19.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMA MAR SA EBITDA is 434.00 K EUR, and current EBITDA margin is 0.26%. See more stats in PHARMA MAR SA financial statements.
Like other stocks, PHME shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMA MAR SA stock right from TradingView charts — choose your broker and connect to your account.